Aim: 12/15-lipoxygenase (12/15-LO) metabolizes arachidonic acid (AA) into several vasoactive eicosanoids. In mouse arteries, we previously characterized the enzyme's 15-LO metabolites 12(S)-hydroxyeicosatetraenoic acid (HETE), 15-HETE, hydroxyepoxyeicosatrienoic acids (HEETAs) and 11,12,12, as endothelium-derived relaxing factors. However, the observed 12-LO metabolites remained uncharacterized. The purpose of this study was to determine the structure and biological functions of eicosanoids generated by the enzyme's 12-LO activity. Methods: Metabolites extracted from aortas of C57BL/6 male mice were separated using a series of reverse and normal phase chromatographic steps and identified as hepoxilin A 3 , trioxilin A 3 and trioxilin C 3 by mass spectrometry. Activities of these natural compounds were tested on isometric tension and intracellular calcium release. The role of thromboxane (TP) receptor was determined in HEK293 cells overexpressing TPa receptor (TPa -HEK). Results: All identified vascular 12-LO metabolites were biologically active. In mouse mesenteric arteries, trioxilin A 3 , C 3 and hepoxilin A 3 (3 lM) relaxed arteries constricted with the thromboxane mimetic, U46619-constricted arteries (maximum relaxations of 78.9 AE 3.2, 29.7 AE 4.6, 82.2 AE 5.0 and 88.0 AE 2.4% respectively), but not phenylephrine-constricted arteries. In TPa-HEK cells, trioxilin A 3 , C 3 and hepoxilin A 3 (10 lM) inhibited U46619 (10 nM)-induced increases in intracellular calcium by 53.0 AE 7.2%, 32.8 AE 5.0% and 37.9 AE 13.5% respectively. In contrast, trioxilin B 3 and hepoxilin B 3 were not synthesized in arteries and exhibited little biological activity. Conclusion: Trioxilin A 3 and C 3 and hepoxilin A 3 are endogenous vascular relaxing factors. They are not endothelium-derived hyperpolarizing factors but mediate vascular relaxation by inhibiting TP agonist-induced increases in intracellular calcium. Thus, they regulate vascular homeostasis by acting as endogenous TP antagonists.
Vascular relaxation is important to oppose vasoconstriction for homeostatic balance and to reduce the impact of cardiovascular diseases such as coronary artery disease and hypertension (Feletou & Vanhoutte 1999 , McGuire et al. 2001 , Campbell & Falck 2007 . Several arachidonic (AA) metabolites cause vascular relaxation and have been targeted for therapeutic development. Endothelial cell cytochrome P450 (CYP450) epoxygenase and cyclooxygenase (COX) metabolize AA to the vasoactive epoxyeicosatrienoic acids and prostacyclin (PGI 2 ) respectively (Campbell & Falck 2007) . A third enzyme, lipoxygenase (LO), is well known for generating leukotrienes, major mediators of inflammation and bronchoconstriction; however, less is known about LO metabolites and their roles in regulating vascular tone (Brash 1999 , Chawengsub et al. 2009a .
Lipoxygenases catalyse dioxygenation of AA into several eicosanoids (Brash 1999) . Leucocyte-type 12/ 15-LO, platelet-type 12-LO and 15-LO are major LOs found in the vasculature (Kim et al. 1995 , Chawengsub et al. 2009a , Gauthier et al. 2011 . The product of 12/15-LO metabolism of AA, 12(S)-hydroperoxyeicosatetraenoic acid (12-HPETE) is reduced to 12(S)-hydroxyeicosatetraenoic acid (12-HETE) or converted to hydroxyl-epoxide containing eicosanoids called hepoxilins (Pace-asciak et al. 1983 , Pace-asciak & Martin 1984 . The epoxy group undergoes hydrolysis resulting in trihydroxy eicosanoids called trioxilins (Pace-asciak 1986) . Several 15-LO products of AA were identified from the endothelium of rabbit arteries including 15(S)-hydroxy-11,12-epoxyeicosatrienoic acid 11, 12, 12, , 12-HETE and 15-HETE, the major metabolite (Campbell et al. 2003 , 2009a . 12, 15 -THETA relaxed rabbit arteries through activation of potassium channels and thus function as endothelium-derived hyperpolarizing factors (EDHF) (Campbell et al. 2003 , 2009a . In the mouse, 12(S)-HETE, 15-HETE, HEETAs and 11,12,15-THETA were isolated from AA metabolism by abdominal aorta, carotid, femoral and mesenteric arteries (Gauthier et al. 2011) . While 15-LO-derived products of AA are more predominant in rabbits, the 12-LO pathway is predominant in mice. We previously showed that 12(S)-HETE, the major LO metabolite in mouse arteries, relaxed mouse mesenteric arteries by antagonizing thromboxane A 2 (TP) receptors (Siangjong et al. 2013) .
Hepoxilins were first identified in rat lung by Paceasciak et al. (1983) . Hepoxilin A 3 was found in rat pancreatic islets, lung, brain, aorta, human platelets and neutrophils (Bryant & Bailey 1979 , Pace-asciak & Martin 1984 , Pace-asciak 1988 , Dho et al. 1990 , Laneuville et al. 1991 . Biological functions of hepoxilin A 3 include stimulation of insulin secretion (Paceasciak & Martin 1984) , modulation of intracellular calcium (Dho et al. 1990) , membrane calcium transport across (Reynaud et al. 1999 ) and neutrophil migration (Reynaud et al. 1999) . The vascular activities of hepoxilin A 3 have not been characterized, particularly in mice. The allylic epoxide group of hepoxilins is reactive and is hydrolysed to stable trioxilins. Trioxilin C 3 caused concentration-dependent relaxation of phenylephrine-contracted rabbit aorta (Pfister 2003) . In this present study, we identified and characterized 12/15(S)-LO metabolites of AA in mouse arteries.
Methods

Animals
Eight-to fourteen-week-old male C57BL6 mice (24-28 g) were obtained from Jackson Laboratory (Bar Harbor, Maine). Animal protocols were approved by the Animal Care Committee of the Medical College of Wisconsin, and procedures were carried out in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals (2011). Mouse aortas were cleaned of connective tissue and placed in cold HEPES buffer (in mM: 10 HEPES, 150 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 6 glucose, pH 7.4) (Gauthier et al. 2011) . The aortas were then incubated with indomethacin (10 lM) for 10 min at 37°C. Subsequently, [
14 C]-arachidonic acid (AA, 0.05 lCi) and unlabelled AA (0.1 lM) were added and further incubated for 5 min. Calcium ionophore A23187 (20 lM) was then added. The reaction was continued at 37°C for another 15 min. Thereafter, ice-cold ethanol was added to a final concentration of 15% to stop the reaction. The incubation buffer was transferred to a glass tube and acidified (pH < 3.5) with glacial acetic acid. The buffer containing [ 14 C]-AA was extracted on Bond Elut C18 extraction columns as previously described . The extracts were dried under a stream of nitrogen gas and stored at À30°C until analysis by HPLC.
Reverse phase (RP)-HPLC separation of AA metabolites
The C18 column extracts containing AA metabolites were reconstituted and separated on a Nucleosil C18 column (5 lm, 4.6 9 250 mm) using solvent system I (Gauthier et al. , 2011 
HPLC determination of THETAs and trioxilins
Column elutes corresponding to THETAs and trioxilins from RP-HPLC using solvent system I were pooled and further resolved on the Nucleosil C18 column using solvent system II as previously described . Solvent A was deionized water containing 0.1% glacial acetic acid and solvent B was acetonitrile. The programme was a 5-min isocratic phase with 35% solvent B in solvent A followed by a 35-min gradient to 85% solvent B. The flow rate was 1 mL min À1 . The absorbance was detected at 205 nm. Fractions of 0.2 mL min À1 were collected and aliquots were measured for radioactivity by a liquid scintillation counter. The purified THETA peak (15.8-18.0 min) from solvent system II was subsequently re-chromatographed on normal phase (NP)-HPLC (a Nucleosil silica column, 5 lm, 4.6 9 250 mm) using solvent system III . The solvent was 95.9 : 4 : 0.1 mixture of hexane : isopropanol : glacial acetic acid. The system was an 80-min isocratic elution with a flow rate of 1 mL min À1 . The absorbance was monitored at 205 nm. Elute fractions of 0.5 mL min À1 were collected and radioactivity was measured by a liquid scintillation counter.
Mass spectrometric analysis
The incubation and extraction of mouse aorta were repeated with 0.1 mM AA, in a similar manner as described above, in the absence of [ 14 C]-AA , Gauthier et al. 2011 . The extracts were resolved on RP-HPLC as described above. Fractions corresponding to HEETA/hepoxilin and THETA/trioxilin standards were collected and extracted with 50 : 50 cyclohexane and ethyl acetate. The organic phase containing HEETAs/hepoxilins or THETAs/trioxilins was collected and evaporated under a stream of nitrogen gas.
The unknown metabolites corresponding to THETAs/trioxilins from HPLC were identified by liquid chromatography-electrospray-Fourier transform ion cyclotron resonance mass spectrometry (LC-ESI-FTICR) (7.0 Tesla FTICR, IonSpec) as previously described (Cui et al. 2008 , Chawengsub et al. 2009b . Detection was made in the negative ion mode, and the ion guides were optimized for m/z 300. The m/z 353 ions were isolated in the ICR cell and fragmented by sustained off-resonance irradiation collision-induced dissociation (SORI-CID) using a nitrogen gas pulse of 20 ms. The FTICR provides a high mass accuracy of fragments for identification of THETAs/trioxilins.
The HEETAs/hepoxilins were analysed by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS/MS, Waters Quattro mass spectrometer with a 2695 liquid chromatograph) (Chawengsub et al. , 2009b . The eicosanoids were separated on a Kromasil C18 column, 250 9 2.0 mm 5 lm (Phenomenex, Torrance, CA) using deionized water (A) and acetonitrile (B) containing 0.005% acetic acid as a mobile phase with a flow rate of 0.2 mL min
À1
. The mobile phase gradient started at 50% B, increased to 70% B over 40 min and to 100% B over 5 min. Detection was made in the negative ion mode. The cone voltage and capillary voltage were set at 19 V and 2.4 kV respectively. MS/ MS ionization was obtained by collision-induced dissociation of the precursor ion m/z 335 using argon as the collision gas. Product ions were detected for the m/z of 50-400. Sample MS/MS spectra and retention times were compared with known standards.
Isometric tension recording
Mouse mesenteric arteries (150-300 lm in diameter) were dissected and cleaned of connective tissues. The arteries were cut into 1.5-to 1.8-mm rings and mounted in a four-chamber wire myograph (Danish MyoTechnology A/S) (Gauthier et al. 2011 , Siangjong et al. 2013 . The arteries were maintained in physiological saline solution (PSS, in mM: 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.17 MgSO 4 , 24 NaHCO 3 , 1.18 KH 2 PO 4 , 0.026 EDTA and 5.5 glucose), at 37°C, supplied with 95% O 2 /5% CO 2 . After 30 min, tension recording was performed as previously described (Gauthier et al. 2011 , Siangjong et al. 2013 . Briefly, the arteries were stretched to a tension of 0.80 mN, where optimum isometric length-tension was achieved (Gauthier et al. 2011) . The arteries were challenged with KCl (60 mM) and the thromboxane mimetic, U46619 (100 nM) 3-4 times until the maximum active tension was established. Thereafter, U46619 or phenylephrine (in the presence of the COX inhibitor indomethacin (10 lM) and the nitric oxide synthase inhibitor, nitro-L-arginine (30 lM)) was added to partially constrict the arteries to approximately 50-70% of maximum active tension. Upon a stable constriction, increasing concentrations of test compounds were added and tension was recorded. In some experiments, the arteries were pre-treated with AUDA (1 lM), a soluble epoxide hydrolase (sEH) inhibitor, for 30 min prior to the constriction (Chawengsub et al. , 2009b . Results are expressed as per cent relaxation with basal tension representing 100% relaxation. In other experiments, arteries were treated with vehicle or trioxilin C 3 (10 lM) for 30 min. Then, constrictor responses to U46619 (10 À8 -10 À6 M) were determined. U46619 constriction responses were expressed as per cent constriction with maximum active tension being 100%.
Cell culture
HEK293 cells overexpressing the human TP a receptor (TP a -HEK) were produced as previously described (Wilson et al. 2004) . The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum, 100 units mL
4 mM L -glutamine and 0.5 mg mL À1 G418. The cells were kept at 37°C in a humidified chamber with 5% CO 2 and 95% O 2 .
Fluorometric imaging plate reader (FLIPR) measurement of intracellular calcium
The calcium assay was performed on a fluorometric imaging plate reader (FLIPR) (Molecular Devices) as previously described (Siangjong et al. 2013) . Briefly, TP a -HEK cells were seeded (5 9 10 4 cells per well)
in phenol red-free growth media in a black CellBIND surface 96-well plate with clear bottoms (Corning). A monolayer of cells at 80-90% confluency was loaded with Fluo-4 calcium dye according to the manufacture's protocol (Fluo-4 NW calcium assay kit, Molecular Probes). Cells were incubated with the dye for 15 min at 37°C followed by an additional 10 min at room temperature. Test compounds, that is vehicle control, hepoxilins and trioxilins, were added to the cells and incubated for 4 min. Subsequently, U46619 was added and the fluorescence was measured. After the assay, cells were lysed with NaOH (2 N) for 2 h at 60°C, followed by HCl (2 N). Samples were then collected and used for protein concentration measurement using the BCA assay (Pierce BCA protein assay kit, Thermo scientific, Waltham, MA, USA 
Data analysis
Data are presented as mean AE SEM. Significant differences between mean values were evaluated by Student's t-test or ANOVA followed by multiple comparison test. P value <0.05 was considered statistically significant.
Results
Incubation of mouse aorta with [ 14 C]-AA in the presence of 10 lM indomethacin resulted in the production of several LO metabolites, which were resolved on RP-HPLC (solvent system I). The products comigrated with standards for THETAs, HEETAs, 15-HETE and 12-HETE (Fig. 1a) . To further purify THETAs, fractions from 5.0 to 7.4 min were pooled and resolved on RP-HPLC using solvent system II (Fig. 1b) . The major peak that eluted at 15.8-18 min was collected and re-chromatographed on NP-HPLC using solvent system III (Fig. 1c) . The radio-chromatogram revealed two products eluting at 51.8 min (peak 1) and 68.0 min (peak 2). These peaks did not co-migrate with THETA standards (11,12,15-THETA, 11,14,15-THETA) that correspond to 15-LO-derived metabolites .
To identify the unknown THETAs, the incubation of mouse aorta was repeated with 10 À4 M unlabelled AA, and the metabolites were extracted and purified on RP-HPLC using solvent systems I and II, and NP-HPLC using solvent system III in the same manner as the radioactive-labelled products (above). NP-HPLC fractions corresponding to peaks 1 and 2 were analysed by LC-ESI-FTICR. The molecular mass [M-H] of both peaks was 353 m z À1 and corresponds to the molecular weight of trioxilins (Fig. 2) . Fragment ions
indicate that the structures of the two metabolites contain three hydroxyls and a carboxyl group. Although the overall major fragment ion spectra of both peaks were similar, the relative ion intensities were clearly different. The most abundant ions of peaks 1 and 2 were 155 m z À1 (Fig. 2a) and 195 m z À1 (Fig. 2b) respectively. This fragmentation profile is useful for predicting their chemical structure. Trioxilin A 3 and C 3 contain hydroxyl (-OH) groups at C8 and C12, but the location of third -OH group differs. While this -OH group is located at C9 in trioxilin C 3 , it is positioned at C11 for trioxilin A 3 . The bond between C8 and C9 of trioxilin C 3 is reactive due to the flanking OH groups. Breakage of this bond gives rise to the fragment ion 155 m z À1 (Fig. 2c) , the most abundant fragment in peak 1 (Fig. 2a) . Likewise, the C11-C12 breakage in trioxilin A 3 results in the ion 195 m z À1 as the most abundant fragment ion (Fig. 2d) ; the same ion profile was observed with the metabolite in peak 2 (Fig. 2b) .
On this basis, peaks 1 and 2 were identified as trioxilin C 3 and trioxilin A 3 respectively. The discovery of trioxilin C 3 and A 3 suggests the synthesis of their precursor, the HEETA-like compound, hepoxilin A 3 . To identify the structure of the unknown HEETA-like products, incubation of mouse aorta was repeated with 10 À4 M of AA, and the metabolites were extracted and resolved on RP-HPLC using solvent system I. We collected the fractions corresponding to HEETAs from RP-HPLC solvent system I (12.8-15.8 min) (Fig. 3a) . The HEETA fractions were pooled and subjected to LC-MS/MS using the negative ion mode. The mass spectrum of the HEETA-like compound is shown in Fig. 3b . The structure prediction of the unknown metabolite was achieved in the same manner as trioxilins (above ]-AA metabolites were resolved on RP-HPLC using solvent system I (a). Fractions co-migrating with THETA standards (5.0-7.4 min) were collected and further separated on RP-HPLC using solvent system II (b). The purified THETA peak (15.8-18.0 min) was re-chromatographed on NP-HPLC using solvent system III (c). The radioactive chromatograph shows two unknown products, peak 1 and 2.
activity of trioxilins and hepoxilins in mouse mesenteric arteries. Synthetic trioxilins were tested for vasorelaxation in arteries constricted with either U46619, a thromboxane A 2 mimetic or phenylephrine, an a 1 -adrenergic receptor agonist. Trioxilin A 3 , B 3 and C 3 caused concentration-related relaxations of U46619-constricted arteries, but not phenylephrineconstricted arteries (Fig. 4a-c) . Maximum relaxations were 78.9 AE 3.2%, 29.7 AE 4.6% and 82.2 AE 5.0% for 3 lM trioxilin A 3 , B 3 and C 3 respectively. The EC 50 values, a concentration that causes 50% maximum effect, were 1.26, 7.15 and 1.00 lM for trioxilin A 3 , B 3 and C 3 respectively. Interestingly, trioxilin B 3 , which was not found in the AA metabolites from mouse aorta, was less potent than trioxilin A 3 and C 3 in relaxing the U46619-constricted arteries. This finding that trioxilins relax mouse mesenteric arteries constricted with a TP agonist, but not an a 1 -adrenergic agonist, suggests that these AA metabolites may competitively displace the thromboxane mimetic U46619 from the TP receptors, thus antagonizing the contraction induced by U46619. This assumption was tested on mesenteric arteries pre-incubated with 10 lM trioxilin C 3 or vehicle. The presence of trioxilin C 3 shifted a constriction curve to increasing concentration of U46619 to the right as compared to vehicletreated vessels (Fig 4d) .
The cis-epoxy isomers of hepoxilin A 3 , 11(R),12(S)-and 11(S),12(R)-hepoxilin A 3 also relaxed U46619-constricted arteries, but not phenylephrine-constricted arteries (Fig. 5a,b) . Thus, the stereochemical configuration of the cis-epoxide does not alter relaxation. Their relaxation responses at 3 lM were 20.0 AE 5.1% and 27.8 AE 6.3% for 11(R),12(S)-and 11(S),12(R)-hepoxilin A 3 respectively. Hepoxilin A 3 -ether, a stable hepoxilin analogue with an ether group between C12 and C13, also caused relaxation of U46619-constricted arteries (Fig. 5c) , with maximal relaxation of 88.0 AE 2.4% at 3 lM. Hepoxilin A 3 -ether also relaxed phenylephrine-constricted arteries by approximately 20%; however, this effect was not statistically significant. Additionally, the relaxations to the hepoxilin A 3 Figure 2 LC-ESI-FTICR mass spectrometry analysis of THETAs. Mass spectrum of peak 1 (a), peak 2 (b), the trioxilin C 3 standard (c) and the trioxilin A 3 standard (d). Detection was made in the negative mode.
isomers were attenuated by the sEH inhibitor, AUDA (1 lM) (maximal relaxations = 10.4 AE 4.3% and 7.1 AE 3.3% respectively) (Fig. 5d,e) . However, AUDA did not alter relaxations of hepoxilin A 3 -ether (Fig. 5f ). This response correlates with the hepoxilin A 3 -ether structure as replacement of the epoxy group with an ether group renders it resistant to sEH metabolism. These data indicate that a portion of the relaxations to hepoxilin A 3 isomers was mediated by the sEH hydrolysis products. A summary of the trioxilin and hepoxilin relaxation responses is shown in Table 2 . To prove further that trioxilins and hepoxilins act as TP receptor antagonists, we examined intracellular calcium concentration responses in HEK293 cells overexpressing the TP a receptor. U46619 (10 nM) increased the calcium-associated fluorescence signal in HEK293 cells overexpressing the TP receptor (Fig. 6a) but was without effect in HEK293 cells without the TP receptor (Fig. 6b) . When the cells were pre-treated with trioxilin A 3 and trioxilin C 3 (10 nM-10 lM), calcium increases induced by U46619 were significantly inhibited in a concentration-dependent manner (Fig. 6c,e) . The calcium-associated fluorescence signals were 53.0 AE 7.2 and 32.8 AE 5.0% for 10 lM trioxilin A 3 and C 3 , respectively, when compared to 100% of vehicle control. In contrast, trioxilin B 3 slightly reduced the calcium increase induced by U46619 at the highest concentration tested (% maximum = 62.7 AE 5.3, Fig. 6d) ; however, this decrease was not statistically significant. These data are consistent with the vascular studies, in which the relaxation response of trioxilin A 3 and C 3 was more potent than trioxilin B 3 . Hepoxilin A 3 -ether at a concentration of 10 lM significantly reduced the U46619-evoked calcium increase (% maximum = 37.9 AE 13.5, Fig. 6f ). The LO metabolites did Values represent Mean AE SEM (n = 8). Values in parentheses were determined in the presence of 1 lM AUDA. Log EC50 represents concentration that causes 50% of the maximum response.
not alter fluorescence when U46619 was not present (data not shown). The calcium assays indicate that 12/ 15-LO metabolites inhibit intracellular calcium increases induced by the TP receptor agonist.
Discussion
Previous studies indicate that vascular LO metabolites are formed in endothelium and their production is greatly diminished if endothelium is removed (Gauthier et al. 2011) . These endothelial LO metabolites of AA regulate vascular tone in arteries from a number of different vasculatures and from various species (Miller et al. 2003 , 2009a , Gauthier et al. 2011 . Recent studies indicate the importance of LO metabolites in the regulation of vascular tone of mouse arteries (Stapleton et al. 2007 , Gauthier et al. 2011 , Kriska et al. 2012 Each value represents the mean AE SEM. n = 6-12. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
et al. 2013). 12(S)-HETE is the major LO metabolite of AA in mouse arteries (Gauthier et al. 2011 , Siangjong et al. 2013 , but numerous other LO metabolites are also present. Therefore, we undertook the identification and characterization of the other 12-LO metabolites. Trioxilin A 3 , trioxilin C 3 and hepoxilin A 3 were identified using a series of HPLC and mass spectrometric analyses. The two trihydroxy eicosanoids were purified using reverse and normal phase HPLC. The unknown products did not co-migrate with a standard of the previously identified mouse THETA, 11,12,15-THETA (Gauthier et al. , 2011 . Subsequently, the structures of trioxilins were identified by mass spectrometry. The relative intensity and major ion fragments of trioxilins from mouse aorta samples were identical to those of the trioxilin A 3 and C 3 standards. The aortic synthesis of trioxilins suggested the existence of their unstable precursor, hepoxilin A 3 . Therefore, the aortic HEETA-like metabolites were purified from HPLC and analysed on LC-MS/MS. Hepoxilin A 3 was identified. The identification of hepoxilin and trioxilins along with 12(S)-HETE supports the dominant role of 12-LO in mouse arteries. This contrasts with the rabbit vasculature in which 15-LO metabolites are predominant (Campbell et al. 2003 , 2009b .
In rabbit arteries, we previously identified several 15-LO-derived metabolites of AA that are relaxing factors (Campbell et al. 2003 , 2009a . 15-H-11,12-EETA and 13-H-14,15-EETA were isolated and identified as endothelial 15-LO metabolites of AA (Campbell et al. 2003 , 2009b . 15-H-11,12-EETA mediated AA-and acetylcholine-induced relaxations in phenylephrine-constricted rabbit aorta and promoted membrane hyperpolarization of rabbit smooth muscle, suggesting that it is an EDHF (Chawengsub et al. , 2009a . It is hydrolysed by sEH to 11,12,15-THETA, which also hyperpolarizes and relaxes rabbit arteries. 11,12,15-THETA relaxation was inhibited by the K channel blocker apamin (Campbell et al. 2003 ). Therefore, 11,12,15-THETA also represents an EDHF in rabbit arteries (Campbell et al. 2003 , Chawengsub et al. 2009a . Endothelial 15-LO is induced by hypoxia, cholesterol, interleukin, oestrogen and other factors resulting in enhanced hyperpolarization and relaxation of smooth muscle . Thus, the 15-LO pathway functions as an inducible EDHF . In comparison, the 15-LO/HEETA/THETA enzymatic pathway in the rabbit vasculature is similar to the 12/15-LO/hepoxilin/trioxilin pathway in mouse arteries.
We investigated the vascular activity of the hepoxilins and trioxilins in mouse mesenteric arteries. In arteries constricted with the thromboxane mimetic, U46619, the hepoxilins and trioxilins caused concentration-related relaxations; however, their potencies varied. Trioxilin A 3 and C 3 , identified as mouse aortic AA metabolites, were more active than trioxilin B 3 . Their potencies were comparable to the stable hepoxilin A 3 -ether. The two epoxy-containing hepoxilin A 3 isomers were less active than the stable hepoxilin-ether analogue and trioxilin A 3 and C 3 . Their reduced activity may be due to their chemical instability in buffer or metabolism by sEH. Instead of enhancing hepoxilin-induced relaxation, sEH inhibition reduced the relaxation responses of the hepoxilin isomers. This indicates that chemical instability, rather than sEH metabolism, accounts for the reduced vasorelaxant activity. Additionally, these data suggest that hepoxilin relaxations in the absence of sEH inhibition are partially mediated by trioxilins. In our previous study of 12(S)-HETE relaxation in mouse mesenteric arteries, the comparison of relaxation responses in either phenylephrine or U46619-constricted arteries provided a useful tool to investigate the role of TP receptors in vasorelaxation (Siangjong et al. 2013) . While 12(S)-HETE had no effect on arteries constricted with the a 1 -adrenergic receptor agonist phenylephrine, it competed with TP receptor agonists to cause relaxation in a concentration-dependent manner (Siangjong et al. 2013) . Similar to 12(S)-HETE, trioxilin A 3 , trioxilin B 3 , trioxilin C 3 and hepoxilin A 3 isomers and ether analogue relaxed the mouse mesenteric arteries constricted with U46619, but not phenylephrine. This suggests a TP receptor-dependent mechanism of relaxation. Contrary to the mouse, trioxilin C 3 caused concentration-dependent relaxation in phenylephrinecontracted rabbit aorta whereas trioxilin A 3 was inactive (Pfister 2003) . This highlights differences in vascular activities of LO metabolites in rabbits and mice. In agreement with our findings in mouse arteries, Qiao et al. (Qiao et al. 2003) . These data and ours indicate that the structure around carbon 11 and 12 may vary greatly and still inhibit TP receptors. The presence of a 12-hydroxy (12-HETE and trioxilin C 3 ), 11,12-dihydroxy (trioxilin A 3 ), 11(R),12(S) or 11(S),12(R) -epoxy (hepoxilin A 3 ), an ether between carbons 11 and 12 (hepoxilin A 3 -ether) or 11,12 cyclopropyl (PBT-3) all inhibit TP receptors. In contrast, the 10,11,12-trihydroxy group of hepoxilin B 3 is not active.
Activation of TP receptors leads to signalling cascades that involve intracellular calcium and Rho kinase (Dorn & Becker 1993 , Klages et al. 1999 , Nakahata 2008 . As calcium is a key second messenger in regulating vascular tone, we used a calciumsensitive fluorescence dye assay to analyse changes in intracellular calcium in HEK293 cells stably expressing the human TP a receptor (Wilson et al. 2004) . We previously showed that the addition of U46619 to TP a -HEK cells caused concentration-dependent increases of calcium-associated fluorescence, which were inhibited by the TP receptor antagonist SQ29548 (Siangjong et al. 2013 ). In the current study, trioxilin C 3 was the most potent 12/15-LO metabolite at inhibiting U46619-induced intracellular calcium increases, which was consistent with the relaxation studies. Trioxilin C 3 was also used to demonstrate the competitive nature of antagonism of U46619-mediated constriction. Hepoxilin A 3 -ether also significantly reduced the calcium increases to U46619. An advantage of using hepoxilin A 3 -ether is that it is more stable than natural hepoxilins that undergo hydrolysis to trioxilins. Similar to our results, Qiao et al. showed that the hepoxilin analogue PBT-3 inhibited intracellular calcium release induced by collagen and I-BOP, a TP receptor agonist (Qiao et al. 2003) . Trioxilin B 3 , which is not synthesized from AA in mouse arteries, was a weak relaxing factor and had no effect on intracellular calcium release evoked by U46619.
Finally, EDHF activity has been defined as endothelium-dependent relaxation that occurs in the presence of NO synthase and cyclooxygenase inhibition and that is absent in arteries constricted by high extracellular potassium (Feletou & Vanhoutte 1999 , Hecker 2000 , McGuire et al. 2001 , Campbell & Falck 2007 . The current studies indicate that this definition is inadequate as it cannot distinguish EDHF from an endogenous antagonist of a constrictor receptor such as a TP receptor antagonist. Measurements of smooth muscle cell membrane potential may also not be useful in defining EDHF as a TP antagonist would repolarize smooth muscle depolarized by U46619. By definition, vasodilators such as EDHF act by a mechanism distal to constrictor receptors and inhibit vasoconstriction by all constrictors. Of course, EDHF will not inhibit vasoconstriction by potassium by virtue of its mechanism of action to activate potassium channels. Thus, in defining EDHF, multiple constrictors, other than potassium, should be tested. EDHF causes endothelium-dependent hyperpolarization and relaxation that occurs in the presence of several vasoconstrictors and that is not inhibited by NO synthase or cyclooxygenase inhibitors.
In summary, we isolated and identified three 12-LO metabolites of AA in mouse arteries: trioxilin A 3 , trioxilin C 3 and hepoxilin A 3 . They reduced intracellular calcium increases induced by a TP receptor agonist and promoted vascular relaxation in mouse mesenteric arteries through TP receptor antagonism. Thus, these 12-LO metabolites have characteristics of endogenous TP receptor antagonists.
Conclusions
In mouse arteries and platelets, LOs metabolize AA to produce 12(S)-HETE, hepoxilin A 3 , trioxilin A 3 and trioxilin C 3 , which act as TP receptor antagonists. On the other hand, under pathological conditions such as stroke, COX is activated in platelets and metabolizes AA to TXA 2 , an endogenous agonist of the TP receptor (Chamorro 2009 ). During oxidative stress, such as hypertension, hypercholesterolaemia or ischaemiareperfusion, AA is oxidized by reactive oxygen species to isoprostanes, which also function as TP receptor agonists (Oguogho et al. 1999 , Yamada et al. 1999 , Dobrian et al. 2001 , Xiao et al. 2001 . While TXA 2 and isoprostanes promote vasoconstriction, the 12-LOderived metabolites act as TP receptor antagonists counteracting the effect of these constrictors. The contrasting effects of these AA metabolites on the same receptor suggest that 12-LO metabolites may represent biologically important endogenous TP antagonists. Vascular homeostasis is tightly regulated by AA metabolites as well as other mechanisms. When TP receptor agonist and antagonist concentrations are balanced, vascular tone and blood pressure are normal. If TXA 2 production is increased or if the 12/15-LO pathway is disrupted, the balance is disturbed and may lead to increased vascular constriction and hypertension.
